Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Print publication year: 2011
  • Online publication date: October 2011

Chapter 16 - Psychiatric illness and psychotropic medication use in epilepsy

Summary

To date neurobiological interest in the behavioral consequences of epilepsy has been concerned primarily with the neuropsychology of temporal lobe epilepsy (TLE) and of mesial temporal lobe epilepsy (mTLE) in particular. In epilepsy several factors can be discerned, which can lead to dynamic and principally reversible changes in the patient's behaviors and mood states. The patient with epilepsy must always be seen in his or her state relative to seizures. Epileptic activity can affect distant brain areas and cause cognitive and behavioral problems beyond the primary lesion. Antiepileptic drugs may have positive or negative psychotropic side effects, and can show incompatibilities in the individual patient. Very special behavioral and neuropsychological conditions are met during nonconvulsive status epilepticus (NCSE). The chapter concludes that in temporal and frontal lobe epilepsy dysfunctional behaviors can be discerned which characteristically correspond to the affected brain regions.

Related content

Powered by UNSILO

References

Ago, J., T. Ishikawa, et al. (2006). “Mechanism of imipramine-induced seizures in amygdala-kindled rats.” Epilepsy Res 72(1): 1–9.
Akiskal, H. S., M. L. Bourgeois, et al. (2000). “Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders.” J Affect Disord 59 Suppl 1: S5–S30.
al-Tajir, G., C. J. Chandler, et al. (1990). “Opposite effects of stimulation of D1 and D2 dopamine receptors on the expression of motor seizures in mouse and rat.” Neuropharmacology 29(7): 657–661.
Albano, C., A. Cupello, et al. (2006). “Successful treatment of epilepsy with serotonin reuptake inhibitors: proposed mechanism.” Neurochem Res 31(4): 509–514.
Alonso, J., A. Buron, et al. (2008). “Association of perceived stigma and mood and anxiety disorders: results from the World Mental Health Surveys.” Acta Psychiatr Scand 118(4): 305–314.
Alper, K. R., J. J. Barry, et al. (2002). “Treatment of psychosis, aggression, and irritability in patients with epilepsy.” Epilepsy Behav 3(5S): 13–18.
Alper, K., K. A. Schwartz, et al. (2007). “Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports.” Biol Psychiatry 62: 345–354.
Amann, B. and H. Grunze (2005). “Neurochemical underpinnings in bipolar disorder and epilepsy.” Epilepsia 46 Suppl 4: 26–30.
Argyropoulos, S. V., J. J. Sandford, et al. (2000). “The psychobiology of anxiolytic drug. Part 2: Pharmacological treatments of anxiety.” Pharmacol Ther 88(3): 213–227.
Armstrong, S. C., K. L. Cozza, et al. (2003). “Six patterns of drug-drug interactions.” Psychosomatics 44(3): 255–258.
Ashton, A. K. (2000). “Lack of desipramine toxicity with citalopram.” J Clin Psychiatry 61(2): 145.
Ashton, H., P. Gallagher, et al. (2006). “The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder.” J Psychopharmacol 20(5): 602–610.
Austin, J. K., J. Harezlak, et al. (2001). “Behavior problems in children before first recognized seizures.” Pediatrics 107(1): 115–122.
Baettig, D., G. Bondolfi, et al. (1993). “Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study.” Eur J Clin Pharmacol 44(4): 403–405.
Bagdy, G., V. Kecskemeti, et al. (2007). “Serotonin and epilepsy.” J Neurochem 100(4): 857–873.
Baldessarini, R. J. and L. Tondo (2000). “Does lithium treatment still work? Evidence of stable responses over three decades.” Arch Gen Psychiatry 57(2): 187–190.
Barone, P., V. Palma, et al. (1991). “Dopamine D1 and D2 receptors mediate opposite functions in seizures induced by lithium-pilocarpine.” Eur J Pharmacol 195(1): 157–162.
Barry, J. J., A. B. Ettinger, et al. (2008). “Consensus statement: the evaluation and treatment of people with epilepsy and affective disorders.” Epilepsy Behav 13 Suppl 1: S1–29.
Barry, J. J. and J. E. Jones (2005). “What is effective treatment of depression in people with epilepsy?Epilepsy Behav 6(4): 520–528.
Behar, D., J. Schaller, et al. (1998). “Extreme reduction of methylphenidate levels by carbamazepine.” J Am Acad Child Adolesc Psychiatry 37(11): 1128–1129.
Bell, G. S. and J. W. Sander (2009). “Suicide and epilepsy.” Curr Opin Neurol 22(2): 174–178.
Berlant, J. L. (2004). “Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder.” BMC Psychiatry 4: 24.
Bernik, M. A., F. M. Corregiari, et al. (2002). “Panic attacks in the differential diagnosis and treatment of resistant epilepsy.” Depress Anxiety 15(4): 190–192.
Besag, F. M. C. (2000). “When is it inappropriate to prescribe psychotropic medication?Epilepsia 43 Suppl 2: 45–50.
Beyenburg, S., A. J. Mitchell, et al. (2005). “Anxiety in patients with epilepsy: systematic review and suggestions for clinical management.” Epilepsy Behav 7(2): 161–171.
Beynon, S., K. Soares-Weiser, et al. (2009). “Pharmacological interventions for the prevention of relapse in bipolar disorder: a systematic review of controlled trials.” J Psychopharmacol 23(5): 574–591.
Biederman, J., T. Spencer, et al. (2004). “Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.” Int J Neuropsychopharmacol 7(1): 77–97.
Billups, S. J., T. Delate, et al. (2009). “Evaluation of risk factors for elevated tricyclic antidepressant plasma concentrations.” Pharmacoepidemiol Drug Saf 18(3): 253–257.
Blum, D., K. Meador, et al. (2006). “Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy.” Neurology 67(3): 400–406.
Blumer, D. (1997). “Antidepressant and double antidepressant treatment for the affective disorder of epilepsy.” J Clin Psychiatry 58(1): 3–11.
Blumer, D., G. Montouris, et al. (2004). “The interictal dysphoric disorder: recognition, pathogenesis, and treatment of the major psychiatric disorder of epilepsy.” Epilepsy Behav 5(6): 826–840.
Blumer, D., S. Wakhlu, et al. (2000). “Treatment of the interictal psychoses.” J Clin Psychiatry 61(2): 110–122.
Bocquillon, P., K. Dujardin, et al. (2009). “Attention impairment in temporal lobe epilepsy: a neurophysiological approach via analysis of the P300 wave.” Hum Brain Mapp 30(7): 2267–2277.
Borowicz, K. K., K. Furmanek-Karwowska, et al. (2009). “Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice.” Psychopharmacology (Berl)doi: 10.1007/s00213-009-1698-x.
Bourgeois, B. F. (1996). “Drug interaction profile of topiramate.” Epilepsia 37 Suppl 2: S14–S17.
Brahm, N. C., G. A. Fast, et al. (2008). “Buspirone for autistic disorder in a woman with an intellectual disability.” Ann Pharmacother 42(1): 131–137.
Brosen, K., J. G. Hansen, et al. (1993). “Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.” Eur J Clin Pharmacol 44(4): 349–355.
Brosen, K. and C. A. Naranjo (2001). “Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.” Eur Neuropsychopharmacol 11(4): 275–283.
Brotherstone, R., B. Blackhall, et al. (2009). “Lengthening of corrected QT during epileptic seizures.” Epilepsiadoi: 10.1111/j.1528-1167.2009.02281.x.
Brown, C., H. C. Schulberg, et al. (1996). “Treatment outcomes for primary care patients with major depression and lifetime anxiety disorders.” Am J Psychiatry 153(10): 1293–1300.
Browning, R. A., A. V. Wood, et al. (1997). “Enhancement of the anticonvulsant effect of fluoxetine following blockade of 5-HT1A receptors.” Eur J Pharmacol 336(1): 1–6.
Burke, W. J. (2004). “Selective versus multi-transmitter antidepressants: are two mechanisms better than one?J Clin Psychiatry 65 Suppl 4: 37–45.
Calabrese, J. R., R. F. Huffman, et al. (2008). “Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials.” Bipolar Disord 10(2): 323–333.
Caplan, J. P., L. A. Epstein, et al. (2008). “Consultants' conflicts: a case discussion of differences and their resolution.” Psychosomatics 49(1): 8–13.
Carey, T. S., C. L. Melvin, et al. (2008). “Extracting key messages from systematic reviews.” J Psychiatr Pract 14 Suppl 1: 28–34.
Casey, D. E. (2006). “Implications of the CATIE trial on treatment: extrapyramidal symptoms.” CNS Spectr 11(7 Suppl 7): 25–31.
Centorrino, F., B. H. Price, et al. (2002). “EEG abnormalities during treatment with typical and atypical antipsychotics.” Am J Psychiatry 159(1): 109–115.
Clark, D. B. and W. S. Agras (1991). “The assessment and treatment of performance anxiety in musicians.” Am J Psychiatry 148(5): 598–605.
Clinckers, R., I. Smolders, et al. (2004). “Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors.” J Neurochem 89(4): 834–843.
Correll, C. U., S. Leucht, et al. (2004). “Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.” Am J Psychiatry 161(3): 414–425.
Coryell, W., J. Endicott, et al. (1988). “Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data.” Am J Psychiatry 145(3): 293–300.
Cramer, J. A., C. Arrigo, et al. (2000). “Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group.” Epilepsia 41(7): 868–874.
Czlonkowska, A. I., M. Zienowicz, et al. (2003). “The role of neurosteroids in the anxiolytic, antidepressive- and anticonvulsive effects of selective serotonin reuptake inhibitors.” Med Sci Monit 9(11): RA270–275.
da Rocha, F. F., T. O. Bamberg, et al. (2009). “Obsessive-compulsive disorder secondary to temporal lobe epilepsy with response to carbamazepine treatment.” Prog Neuropsychopharmacol Biol Psychiatry 33(3): 568–569.
Dailey, J. W. and D. K. Naritoku (1996). “Antidepressants and seizures: clinical anecdotes overshadow neuroscience.” Biochem Pharmacol 52(9): 1323–1329.
Davidson, J. R. (2009). “First-line pharmacotherapy approaches for generalized anxiety disorder.” J Clin Psychiatry 70 Suppl 2: 25–31.
De Dios, C., E. Ezquiaga, et al. (2009). “Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: a prospective, 18-month follow-up study.”J Affect Disord; in press.
de Freitas, R. L., I. M. Santos, et al. (2009). “Oxidative stress in rat hippocampus caused by pilocarpine-induced seizures is reversed by buspirone.” Brain Res Bulldoi: 10.1016/j.brainresbull.2009.09.014.
de Leon, J., B. Greenlee, et al. (2009). “Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities.” Res Dev Disabil 30: 613–669.
de Souza, E. A. and P. C. Salgado (2006). “A psychosocial view of anxiety and depression in epilepsy.” Epilepsy Behav 8(1): 232–238.
Degner, D., R. Grohmann, et al. (2004). “Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP.” Pharmacopsychiatry 37 Suppl 1: S39–45.
Denney, D. and J. R. Stevens (1995). “Clozapine and seizures.” Biol Psychiatry 37(7): 427–433.
Deutsch, S. I., R. B. Rosse, et al. (2009). “Temporal lobe epilepsy confused with panic disorder: implications for treatment.” Clin Neuropharmacol 32(3): 160–162.
Donovan, M. R., P. Glue, et al. (2010). “Comparative efficacy of antidepressants in preventing relapse in anxiety disorders: a meta-analysis.” J Affect Disord 123(1): 9–16.
Dunn, D. W., J. K. Austin, et al. (2003). “ADHD and epilepsy in childhood.” Dev Med Child Neurol 45(1): 50–54.
Dunner, D. L., S. Zisook, et al. (1998). “A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.” J Clin Psychiatry 59(7): 366–373.
Edwards, S. J. and C. J. Smith (2009). “Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.” Clin Ther 31(Pt 1): 1345–1359.
Elliott, B., E. Joyce, et al. (2009). “Delusions, illusions and hallucinations in epilepsy: 2. complex phenomena and psychosis.” Epilepsy Res 85: 172–186.
Ereshefsky, L. (1996). “Drug-drug interactions involving antidepressants: focus on venlafaxine.” J Clin Psychopharmacol 16(3 Suppl 2): 37S–50S; discussion 50S–53S.
Ettinger, A. B. (2006). “Psychotropic effects of antiepileptic drugs.” Neurology 67: 1916–1925.
Ettinger, A. B., L. A. Copeland, et al. (2010). “Are psychiatric disorders independent risk factors for new-onset epilepsy in older individuals?Epilepsy Behav 17: 70–74.
Ettinger, A. B., M. L. Reed, et al. (2005). “Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders.” Neurology 65(4): 535–540.
Ettinger, A. B., R. P. Kustra, et al. (2007). “Effect of lamotrigine on depressive symptoms in adult patients with epilepsy.” Epilepsy Behav 10(1): 148–154.
Fakhoury, T. A., J. J. Barry, et al. (2007). “Lamotrigine in patients with epilepsy and comorbid depressive symptoms.” Epilepsy Behav 10(1): 155–162.
Fang, S. Y., C. Y. Chen, et al. (2009). “Predictors of the incidence and discontinuation of long-term use of benzodiazepines: a population-based study.” Drug Alcohol Depend 104(1–2): 140–146.
Farooq, S. and A. Sherin (2008). “Interventions for psychotic symptoms concomitant with epilepsy.” Cochrane Database Syst Rev(4): CD006118.
Fastenau, P. S., C. S. Johnson, et al. (2009). “Neuropsychological status at seizure onset in children: risk factors for early cognitive deficits.” Neurology 73(7): 526–534.
Fava, M., A. J. Rush, et al. (2005). “15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL.” Prim Care Companion J Clin Psychiatry 7(3): 106–113.
Favale, E., D. Audenino, et al. (2003). “The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis.” Seizure 12(5): 316–318.
Favale, E., V. Rubino, et al. (1995). “Anticonvulsant effect of fluoxetine in humans.” Neurology 45(10): 1926–1927.
Feldman, H., P. Crumrine, et al. (1989). “Methylphenidate in children with seizures and attention-deficit disorder.” Am J Dis Child 143(9): 1081–1086.
Fleming, J. and M. Chetty (2005). “Psychotropic drug interactions with valproate.” Clin Neuropharmacol 28(2): 96–101.
Flockhart, D. (2007, January 12, 2009). “Drug Interactions: Cytochrome P450 Drug Interaction Table.” Retrieved 11 October 2009, from http://medicine.iupui.edu/clinpharm/ddis/table.asp.
Flores, G., S. Perez-Patrigeon, et al. (2004). “Severe symptomatic hyponatremia during citalopram therapy: a case report.” BMC Nephrol 5: 2.
Freitas, R. M., F. C. Sousa, et al. (2006). “Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus.” Neurosci Lett 408(2): 79–83.
Garner, M., H. Mohler, et al. (2009). “Research in anxiety disorders: from the bench to the bedside.” Eur Neuropsychopharmacol 19(6): 381–390.
Gates, J. R. (2000). “Side effect profiles and behavioral consequences of antiepileptic medications.” Epilepsy Behav 1(3): 153–159.
Gayatri, N. A. and J. H. Livingston (2006). “Aggravation of epilepsy by anti-epileptic drugs.” Dev Med Child Neurol 48(5): 394–398.
Geddes, J. R., J. R. Calabrese, et al. (2009). “Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials.” Br J Psychiatry 194(1): 4–9.
Gillman, P. K. (2007). “Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.” Br J Pharmacol 151(6): 737–748.
Gonzalez-Heydrich, J., M. Weiss, et al. (2006). “Pharmacological management of a youth with ADHD and a seizure disorder.” J Am Acad Child Adolesc Psychiatry 45(12): 1527–1532.
Goodwin, G. M., I. Anderson, et al. (2008). “ECNP consensus meeting. Bipolar depression. NICE, March 2007.” Eur Neuropsychopharmacol 18(7): 535–549.
Grabowska-Grzyb, A., J. Jedrzejczak, et al. (2006). “Risk factors for depression in patients with epilepsy.” Epilepsy Behav 8(2): 411–417.
Greenhill, L. L., S. Pliszka, et al. (2002). “Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.” J Am Acad Child Adolesc Psychiatry 41(2 Suppl): 26S–49S.
Greenwood, R. S. (2000). “Adverse effects of antiepileptic drugs.” Epilepsia 41 Suppl 2: S42–52.
Gross, A., O. Devinsky, et al. (2000). “Psychotropic medication use in patients with epilepsy: effect on seizure frequency.” J Neuropsychiatry Clin Neurosci 12(4): 458–464.
Gross-Tsur, V. (1999). “Carbamazepine and methylphenidate.” J Am Acad Child Adolesc Psychiatry 38(6): 637.
Gross-Tsur, V., O. Manor, et al. (1997). “Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective?J Pediatr 130(4): 670–674.
Gucuyener, K., A. K. Erdemoglu, et al. (2003). “Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities.” J Child Neurol 18(2): 109–112.
Gumnit, R. J. and T. S. Walczak (2001). “Guidelines for essential services, personnel, and facilities in specialized epilepsy centers in the United States.” Epilepsia 42(6): 804–814.
Haddad, P. M. and S. M. Dursun (2008). “Neurological complications of psychiatric drugs: clinical features and management.” Hum Psychopharmacol 23 Suppl 1: 15–26.
Harden, C. L., M. C. Pulver, et al. (2000). “A pilot study of mood in epilepsy patients treated with vagus nerve stimulation.” Epilepsy Behav 1(2): 93–99.
Hemmer, S. A., J. F. Pasternak, et al. (2001). “Stimulant therapy and seizure risk in children with ADHD.” Pediatr Neurol 24(2): 99–102.
Henderson, D. C. and P. M. Doraiswamy (2008). “Prolactin-related and metabolic adverse effects of atypical antipsychotic agents.” J Clin Psychiatry 69 Suppl 1: 32–44.
Hernandez, A. and P. Barragan (2005). “Efficacy of atomoxetine treatment in children with ADHD and epilepsy.” Epilepsia 46 Suppl 6: 239.
Hesdorffer, D. C., P. Ludvigsson, et al. (2004). “ADHD as a risk factor for incident unprovoked seizures and epilepsy in children.” Arch Gen Psychiatry 61: 731–736.
Hoffman, E. J. and S. J. Mathew (2008). “Anxiety disorders: a comprehensive review of pharmacotherapies.” Mt Sinai J Med 75(3): 248–262.
Hovorka, J., E. Herman, et al. (2000). “Treatment of interictal depression with citalopram in patients with epilepsy.” Epilepsy Behav 1(6): 444–447.
Hughes, J. R., A. J. DeLeo, et al. (2000). “The electroencephalogram in attention deficit-hyperactivity disorder: emphasis on epileptiform discharges.” Epilepsy Behav 1(4): 271–277.
Jobe, P. C. and R. A. Browning (2005). “The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant.” Epilepsy Behav 7(4): 602–619.
Joffe, R. T., R. M. Bagby, et al. (1993). “Anxious and nonanxious depression.” Am J Psychiatry 150(8): 1257–1258.
Johnson, E. K., J. E. Jones, et al. (2004). “The relative impact of anxiety, depression, and clinical seizure features on health-related quality of life in epilepsy.” Epilepsia 45(5): 544–550.
Jones, J. E., B. P. Hermann, et al. (2005). “Clinical assessment of Axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation.” J Neuropsychiatry Clin Neurosci 17(2): 172–179.
Jones, J. E., R. Watson, et al. (2007). “Psychiatric comorbidity in children with new onset epilepsy.” Dev Med Child Neurol 49: 493–497.
Jones, P. B., T. R. Barnes, et al. (2006). “Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1).” Arch Gen Psychiatry 63(10): 1079–1087.
Judd, L. L. and H. S. Akiskal (2003). “Depressive episodes and symptoms dominate the longitudinal course of bipolar disorder.” Curr Psychiatry Rep 5(6): 417–418.
Kalogjera-Sackellares, D. and J. C. Sackellares (2002). “Improvement in depression associated with partial epilepsy in patients treated with lamotrigine.” Epilepsy Behav 3(6): 510–516.
Kane, J. M., S. Leucht, et al. (2003). “The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.” J Clin Psychiatry 64 Suppl 12: 5–19.
Kanner, A. M. (2000). “Psychosis of epilepsy: a neurologist's perspective.” Epilepsy Behav 1(4): 219–227.
Kanner, A. M. (2003). “When did neurologists and psychiatrists stop talking to each other?Epilepsy Behav 4(6): 597–601.
Kanner, A. M. (2004). “Recognition of the various expressions of anxiety, psychosis, and aggression in epilepsy.” Epilepsia 45 Suppl 2: 22–27.
Kanner, A. M. (2009). “Psychiatric issues in epilepsy: the complex relation of mood, anxiety disorders, and epilepsy.” Epilepsy Behav 15(1): 83–87.
Kanner, A. M. and B. E. Gidal (2008). “Pharmacodynamic and pharmacokinetic interactions of psychotropic drugs with antiepileptic drugs.” Int Rev Neurobiol 83: 397–416.
Kanner, A. M., A. M. Kozak, et al. (2000). “The use of sertraline in patients with epilepsy: is it safe?Epilepsy Behav 1(2): 100–105.
Kanner, A. M., J. Wuu, et al. (2003). “A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events.” Epilepsy Behav 4(5): 548–552.
Katon, W. J. and M. Seelig (2008). “Population-based care of depression: team care approaches to improving outcomes.” J Occup Environ Med 50(4): 459–467.
Kaufman, K. R. and R. Gerner (1998). “Lamotrigine toxicity secondary to sertraline.” Seizure 7(2): 163–165.
Kaufmann, R., H. Goldberg-Stern, et al. (2009). “Attention-deficit disorders and epilepsy in childhood: incidence, causative relations and treatment possibilities.” J Child Neurol 24(6): 727–733.
Keller, M. B., J. H. Krystal, et al. (2005). “Untangling depression and anxiety: clinical challenges.” J Clin Psychiatry 66(11): 1477–1484.
Kent, J. M., S. J. Mathew, et al. (2002). “Molecular targets in the treatment of anxiety.” Biol Psychiatry 52(10): 1008–1030.
Kettl, P. A. and I. M. Marks (1986). “Neurological factors in obsessive compulsive disorder: two case reports and a review of the literature.” Br J Psychiatry 149: 315–319.
Kim, J. and J. Gorman (2005). “The psychobiology of anxiety.” Clin Neurosci Res 4: 335–347.
Kirov, G. and J. Tredget (2005). “Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series.” BMC Psychiatry 5: 19.
Koponen, H. J., E. Leinonen, et al. (1996). “Fluvoxamine increases the clozapine serum levels significantly.” Eur Neuropsychopharmacol 6(1): 69–71.
Kossoff, E. H., G. K. Bergey, et al. (2001). “Levetiracetam psychosis in children with epilepsy.” Epilepsia 42(12): 1611–1613.
Krishnamoorthy, E. S., M. R. Trimble, et al. (2002). “Forced normalization at the interface between epilepsy and psychiatry.” Epilepsy Behav 3(4): 303–308.
Kühn, K. U., B. B. Quednow, et al. (2003). “Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants.” Epilepsy Behav 4(6): 674–679.
Kupka, R. W., L. L. Altshuler, et al. (2007). “Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder.” Bipolar Disord 9(5): 531–535.
Labiner, D. M., A. B. Ettinger, et al. (2009). “Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy.” Epilepsia 50(3): 434–442.
Lamberty, Y., D. G. Margineanu, et al. (2000). “Absence of negative impact of levetiracetam on cognitive function and memory in normal and amygdala-kindled rats.” Epilepsy Behav 1(5): 333–342.
Langosch, J. M. and M. R. Trimble (2002). “Epilepsy, psychosis and clozapine.” Hum Psychopharmacol 17(2): 115–119.
Laruelle, M., W. G. Frankle, et al. (2005). “Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.” Clin Ther 27 Suppl A: S16–24.
Lau, C., A. B. Ettinger, et al. (2010). Do mood instability symptoms in epilepsy represent formal bipolar disorder? (Abstract). American Academy of Neurology meetings, Toronto, Canada.
Law, S. F. and R. J. Schachar (1999). “Do typical clinical doses of methylphenidate cause tics in children treated for attention-deficit hyperactivity disorder?J Am Acad Child Adolesc Psychiatry 38(8): 944–951.
Ledoux, T., M. D. Barnett, et al. (2009). “Predictors of recent mental health service use in a medical population: implications for integrated care.” J Clin Psychol Med Settings 16(4): 304–310.
Lehman, A. F., J. A. Lieberman, et al. (2004). “Practice guideline for the treatment of patients with schizophrenia, second edition.” Am J Psychiatry 161(2 Supplement): 1–56.
Leucht, S., K. Komossa, et al. (2009). “A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.” Am J Psychiatry 166(2): 152–163.
Levenson, J. L. (2008). “Psychiatric issues in neurology, Part 3: epilepsy.” Primary Psychiatry 15(1): 21–25.
Lindley, S. E., E. B. Carlson, et al. (2007). “A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder.” J Clin Psychopharmacol 27(6): 677–681.
Lopez-Gomez, M., M. Espinola, et al. (2008). “Clinical presentation of anxiety among patients with epilepsy.” Neuropsychiatr Dis Treat 4(6): 1235–1239.
Lopez-Gomez, M., J. Ramirez-Bermudez, et al. (2005). “Primidone is associated with interictal depression in patients with epilepsy.” Epilepsy Behav 6(3): 413–416.
Loring, D. W., S. Marino, et al. (2007). “Neuropsychological and behavioral effects of antiepilepsy drugs.” Neuropsychol Rev 17(4): 413–425.
Macêdo, D. S., R. S. Santos, et al. (2004). “Effect of anxiolytic, antidepressant, and antipsychotic drugs on cocaine-induced seizures and mortality.” Epilepsy Behav 5(6): 852–856.
Malhi, G. S., D. Adams, et al. (2009). “Medicating mood with maintenance in mind: bipolar depression pharmacotherapy.” Bipolar Disord 11 Suppl 2: 55–76.
Mamiya, K., K. Kojima, et al. (2001). “Phenytoin intoxication induced by fluvoxamine.” Ther Drug Monit 23(1): 75–77.
Maramattom, B. V. (2006). “Duloxetine-induced syndrome of inappropriate antidiuretic hormone secretion and seizures.” Neurology 66(5): 773–774.
Martin, J. L., M. Sainz-Pardo, et al. (2007). “Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials.” J Psychopharmacol 21(7): 774–782.
Mathews, M. and D. J. Muzina (2007). “Atypical antipsychotics: new drugs, new challenges.” Cleve Clin J Med 74(8): 597–606.
Mazza, M., G. Della Marca, et al. (2007). “Oxcarbazepine improves mood in patients with epilepsy.” Epilepsy Behav 10(3): 397–401.
McBride, M. C., D. D. Wang, et al. (1986). “Methylphenidate in therapeutic doses does not lower seizure threshold.” Ann Neurol 20(3): 428.
McElroy, S. L., B. E. Martens, et al. (2010). “Placebo-controlled study of quetiapine monotherapy in ambulatory bipolar spectrum disorder with moderate-to-severe hypomania or mild mania.” J Affect Disord124(1–2): 157–163.
Melkersson, K. (2005). “Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients.” J Clin Psychiatry 66(6): 761–767.
Mello, M. F., M. S. Yeh, et al. (2009). “A randomized, double-blind, placebo-controlled trial to assess the efficacy of topiramate in the treatment of post-traumatic stress disorder.” BMC Psychiatry 9: 28.
Mensah, S. A., J. M. Beavis, et al. (2007). “A community study of the presence of anxiety disorder in people with epilepsy.” Epilepsy Behav 11(1): 118–124.
Meyer, J. M. and S. M. Stahl (2009). “The metabolic syndrome and schizophrenia.” Acta Psychiatr Scand 119(1): 4–14.
Miyamoto, T., M. Kohsaka, et al. (2000). “Psychotic episodes during zonisamide treatment.” Seizure 9(1): 65–70.
Mohamed, S., K. Osatuke, et al. (2006). “Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.” Am J Geriatr Pharmacother 4(3): 201–209.
Mohler, H., J. M. Fritschy, et al. (2002). “A new benzodiazepine pharmacology.” J Pharmacol Exp Ther 300(1): 2–8.
Moller, S. E., F. Larsen, et al. (2001). “Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects.” J Clin Psychopharmacol 21(5): 493–499.
Monaco, F., A. Cavanna, et al. (2005). “Obsessionality, obsessive-compulsive disorder, and temporal lobe epilepsy.” Epilepsy Behav 7(3): 491–496.
Montenegro, M. A., H. Arif, et al. (2008). “Efficacy of clobazam as add-on therapy for refractory epilepsy: experience at a US epilepsy center.” Clin Neuropharmacol 31(6): 333–338.
Montgomery, S., K. Chatamra, et al. (2008). “Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder.” Br J Psychiatry 193(5): 389–394.
Montgomery, S. A., K. Tobias, et al. (2006). “Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine.” J Clin Psychiatry 67(5): 771–782.
Moore, J. L., J. W. McAuley, et al. (2002). “An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients.” Epilepsy Behav 3(1): 92–95.
Morishita, S. (2009). “Clonazepam as a therapeutic adjunct to improve the management of depression: a brief review.” Hum Psychopharmacol 24(3): 191–198.
Mostert, J. P., M. W. Koch, et al. (2008). “Therapeutic potential of fluoxetine in neurological disorders.” CNS Neurosci Ther 14(2): 153–164.
Mula, M., D. C. Hesdorffer, et al. (2009a). “The role of titration schedule of topiramate for the development of depression in patients with epilepsy.” Epilepsia 50(5): 1072–1076.
Mula, M., R. Jauch, et al. (2009b). “Manic/hypomanic symptoms and quality of life measures in patients with epilepsy.” Seizure 18(7): 530–532.
Mula, M. and F. Monaco (2002). “Carbamazepine-risperidone interactions in patients with epilepsy.” Clin Neuropharmacol 25(2): 97–100.
Mula, M. and F. Monaco (2009). “Antiepileptic drugs and psychopathology of epilepsy: an update.” Epileptic Disord 11(1): 1–9.
Mula, M., S. Pini, et al. (2007). “The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.” J Clin Psychopharmacol 27(3): 263–272.
Mula, M. and J. W. Sander (2007). “Suicidal ideation in epilepsy and levetiracetam therapy.” Epilepsy Behav 11(1): 130–132.
Mula, M., B. Schmitz, et al. (2008). “On the prevalence of bipolar disorder in epilepsy.” Epilepsy Behav 13(4): 658–661.
Mula, M. and M. R. Trimble (2003). “The importance of being seizure free: topiramate and psychopathology in epilepsy.” Epilepsy Behav 4(4): 430–434.
Mula, M., M. R. Trimble, et al. (2007). “Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.” Epilepsia 48(12): 2322–2326.
Mylan Pharmaceutical Drug Information (2007a). On clomipramine hydrochloride, available at: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=5794.
Mylan Pharmaceutical Drug Information (2007b). On maprotiline hydrochloride, available at: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=5899.
Nadkarni, S., V. Arnedo, et al. (2007). “Psychosis in epilepsy patients.” Epilepsia 48 Suppl 9: 17–19.
Nasrallah, H. (2003). “A review of the effect of atypical antipsychotics on weight.” Psychoneuroendocrinology 28 Suppl 1: 83–96.
Nelson, J. C., C. M. Mazure, et al. (2004). “Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.” Biol Psychiatry 55(3): 296–300.
Nemeroff, C. B., S. H. Preskorn, et al. (2007). “Antidepressant drug-drug interactions: clinical relevance and risk management.” CNS Spectr 12(5 Suppl 7): 1–13.
Newcomer, J. W., R. E. Ratner, et al. (2009). “A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.” J Clin Psychiatry 70(4): 487–499.
Newcorn, J. H. and C. Donnelly (2009). “Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder.” Mt Sinai J Med 76(2): 198–203.
Nilsson, L., A. Ahlbom, et al. (2002). “Risk factors for suicide in epilepsy: a case control study.” Epilepsia 43(6): 644–651.
Novick, D., A. Gonzalez-Pinto, et al. (2009). “Translation of randomised controlled trial findings into clinical practice: comparison of olanzapine and valproate in the EMBLEM study.” Pharmacopsychiatry 42(4): 145–152.
Novick, D., J. M. Haro, et al. (2009). “Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.” Eur Neuropsychopharmacol 19(8): 542–550.
Onder, E., U. Tural, et al. (2008). “Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?Eur Arch Psychiatry Clin Neurosci 258(6): 319–323.
Pande, A. C., J. R. Davidson, et al. (1999). “Treatment of social phobia with gabapentin: A placebo-controlled study.” J Clin Psychopharmacol 19(4): 341–348.
Pande, A. C., D. E. Feltner, et al. (2004). “Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.” J Clin Psychopharmacol 24(2): 141–149.
Pande, A. C., M. H. Pollack, et al. (2000). “Placebo-controlled study of gabapentin treatment of panic disorder.” J Clin Psychopharmacol 20(4): 467–471.
Papakostas, G. I., M. E. Thase, et al. (2007). “Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.” Biol Psychiatry 62(11): 1217–1227.
Parisi, P., R. Moavero, et al. (2009). “Attention deficit hyperactivity disorder in children with epilepsy.” Brain Devdoi: 10.1016/j.braindev.2009.03.005.
Patsalos, P. N. and E. Perucca (2003a). “Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs.” Lancet Neurol 2(6): 347–356.
Patsalos, P. N. and E. Perucca (2003b). “Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.” Lancet Neurol 2(8): 473–481.
PDR (2010a). “Adderall tablets concise monograph,” retrieved on 12 January 2010 from http://www.pdr.net/drugpages/concisemonograph.aspx?concise=1400.
PDR (2010b). “Ritalin tablets concise monograph,” retrieved on 12 January 2010 from http://www.pdr.net/drugpages/concisemonograph.aspx?concise=941.
Peritogiannis, V., S. Tsouli, et al. (2005). “Acute effects of clozapine-fluvoxamine combination.” Schizophr Res 79(2–3): 345–346.
Perucca, E. (2005). “Clinically relevant drug interactions with antiepileptic drugs.” Br J Clin Pharmacol 61(3): 246–255.
Perucca, P., J. Carter, et al. (2009). “Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy.” Neurology 72(14): 1223–1229.
Phelps, J., J. Angst, et al. (2008). “Validity and utility of bipolar spectrum models.” Bipolar Disord 10(1 Pt 2): 179–193.
Pisani, F., E. Spina, et al. (1999). “Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice.” Epilepsia 40 Suppl 10: S48–56.
Pohl, R. B., D. E. Feltner, et al. (2005). “Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of bid versus tid dosing.” Journal of Clinical Psychopharmacology 25(2): 151–157.
Pollack, M. H. (2009). “Refractory generalized anxiety disorder.” J Clin Psychiatry 70 Suppl 2: 32–38.
Pollack, M. H., J. Tiller, et al. (2008). “Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.” J Clin Psychopharmacol 28(3): 308–316.
Popli, A. P., J. C. Kando, et al. (1995). “Occurrence of seizures related to psychotropic medication among psychiatric inpatients.” Psychiatr Serv 46(5): 486–488.
Post, R. M. (2009). “Myth of evidence-based medicine for bipolar disorder.” Expert Rev Neurother 9(9): 1271–1273.
Price, B. H., R. D. Adams, et al. (2000). “Neurology and psychiatry: closing the great divide.” Neurology 54(1): 8–14.
Prueter, C. and C. Norra (2005). “Mood disorders and their treatment in patients with epilepsy.” J Neuropsychiatry Clin Neurosci 17(1): 20–28.
Qin, P., H. Xu, et al. (2005). “Risk for schizophrenia and schizophrenia-like psychosis among patients with epilepsy: population based cohort study.” BMJ 331(7507): 23.
Redmond, J. R., K. L. Jamison, et al. (2006). “Lamotrigine combined with divalproex or lithium for bipolar disorder: a case series.” CNS Spectr 11(12): 915–918.
Reimers, A., E. Skogvoll, et al. (2005). “Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service.” J Clin Psychopharmacol 25(4): 342–348.
Reynolds, E. H. and M. R. Trimble (2009). “Epilepsy, psychiatry, and neurology.” Epilepsia 50 Suppl 3: 50–55.
Richelson, E. (2003). “Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance.” J Clin Psychiatry 64 Suppl 13: 5–12.
Richer, L. P., M. I. Shevell, et al. (2002). “Epileptiform abnormalities in children with attention-deficit-hyperactivity disorder.” Pediatr Neurol 26(2): 125–129.
Rickels, K., M. H. Pollack, et al. (2005). “Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.” Arch Gen Psychiatry 62(9): 1022–1030.
Riss, J., J. Cloyd, et al. (2008). “Benzodiazepines in epilepsy: pharmacology and pharmacokinetics.” Acta Neurol Scand 118(2): 69–86.
Rubio, G., M. A. Jimenez-Arriero, et al. (2006). “The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder.” J Clin Psychopharmacol 26(3): 341–344.
Rush, A. J., M. S. George, et al. (2000). “Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study.” Biol Psychiatry 47(4): 276–286.
Rzezak, P., D. Fuentes, et al. (2007). “Frontal lobe dysfunction in children with temporal lobe epilepsy.” Pediatr Neurol 37(3): 176–185.
Sabaawi, M., N. N. Singh, et al. (2006). “Guidelines for the use of clozapine in individuals with developmental disabilities.” Res Dev Disabil 27(3): 309–336.
Sachdev, P. S. (2007). “Alternating and postictal psychoses: review and a unifying hypothesis.” Schizophr Bull 33(4): 1029–1037.
Saegusa, S., T. Takahashi, et al. (2004). “Panic attack symptoms in a patient with left temporal lobe epilepsy.” J Int Med Res 32(1): 94–96.
Sazgar, M., P. L. Carlen, et al. (2003). “Panic attack semiology in right temporal lobe epilepsy.” Epileptic Disord 5(2): 93–100.
Schaller, J. L. and D. Behar (1999). “Carbamazepine and methylphenidate in ADHD.” J Am Acad Child Adolesc Psychiatry 38(2): 112–113.
Schatzberg, A. F. (2007). “Safety and tolerability of antidepressants: weighing the impact on treatment decisions.” J Clin Psychiatry 68 Suppl 8: 26–34.
Scherk, H., F. G. Pajonk, et al. (2007). “Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.” Arch Gen Psychiatry 64(4): 442–455.
Scherkl, R., A. Hashem, et al. (1991). “Histamine in brain – its role in regulation of seizure susceptibility.” Epilepsy Res 10(2–3): 111–118.
Schmitz, B. (2005). “Depression and mania in patients with epilepsy.” Epilepsia 46 Suppl 4: 45–49.
Schonfeldt-Lecuona, C., R. C. Wolf, et al. (2009). “Pregabalin in the treatment of schizophrenic anxiety.” Pharmacopsychiatry 42(3): 124–125.
Schubert, R. (2005). “Attention deficit disorder and epilepsy.” Pediatr Neurol 32(1): 1–10.
Shehata, G. A., A. Bateh Ael, et al. (2009). “Neuropsychological effects of antiepileptic drugs (carbamazepine versus valproate) in adult males with epilepsy.” Neuropsychiatr Dis Treat 5: 527–533.
Sheth, R. D., N. Binkley, et al. (2008). “Progressive bone deficit in epilepsy.” Neurology 70(3): 170–176.
Smith, L. A., V. R. Cornelius, et al. (2009). “Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis.” J Affect Disorddoi: 10.1016/j.jad.2009.10.033.
Smolders, I., R. Clinckers, et al. (2008). “Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action.” Neuropharmacology 54(6): 1017–1028.
Somerville, E. R. (2002). “Aggravation of partial seizures by antiepileptic drugs: is there evidence from clinical trials?Neurology 59(1): 79–83.
Specchio, L. M., A. Iudice, et al. (2004). “Citalopram as treatment of depression in patients with epilepsy.” Clin Neuropharmacol 27(3): 133–136.
Spina, E., A. Avenoso, et al. (2002). “Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction.” J Clin Psychopharmacol 22(4): 419–423.
Spina, E., C. D'Arrigo, et al. (2006). “Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder.” Ther Drug Monit 28(5): 599–602.
Spina, E., C. D'Arrigo, et al. (2009). “Effect of valproate on olanzapine plasma concentrations in patients with bipolar or schizoaffective disorder.” Ther Drug Monit 31(6): 758–763.
Spina, E. and E. Perucca (2002). “Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs.” Epilepsia 43 Suppl 2: 37–44.
Spina, E., M. G. Scordo, et al. (2003). “Metabolic drug interactions with new psychotropic agents.” Fundam Clin Pharmacol 17(5): 517–538.
Starr, M. S. (1996). “The role of dopamine in epilepsy.” Synapse 22(2): 159–194.
Sullivan, G. M., J. D. Coplan, et al. (1999). “The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias.” Biol Psychiatry 46(9): 1205–1218.
Sun, X. Y., L. Zhang, et al. (2009). “Characterization of the anticonvulsant activity of doxepin in various experimental seizure models in mice.” Pharmacol Rep 61(2): 245–251.
Susman, J. and B. Klee (2005). “The role of high-potency benzodiazepines in the treatment of panic disorder.” Prim Care Companion J Clin Psychiatry 7(1): 5–11.
Swartz, M. S., T. S. Stroup, et al. (2008). “What CATIE found: results from the schizophrenia trial.” Psychiatr Serv 59(5): 500–506.
Tadokoro, Y., T. Oshima, et al. (2007). “Interictal psychoses in comparison with schizophrenia: a prospective study.” Epilepsia 48(12): 2345–2351.
Tan, M. and R. Appleton (2005). “Attention deficit and hyperactivity disorder, methylphenidate, and epilepsy.” Arch Dis Child 90(1): 57–59.
Tanaka, E. (1999). “Clinically significant pharmacokinetic drug interactions with benzodiazepines.” J Clin Pharm Ther 24: 347–355.
Tarulli, A., O. Devinsky, et al. (2001). “Progression of postictal to interictal psychosis.” Epilepsia 42(11): 1468–1471.
Tondo, L., R. J. Baldessarini, et al. (1998). “Lithium treatment and risk of suicidal behavior in bipolar disorder patients.” J Clin Psychiatry 59(8): 405–414.
Torres, A. R., J. Whitney, et al. (2008). “Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment.” Epilepsy Behav 12(2): 217–233.
Torta, R. and F. Monaco (2002). “Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations.” Epilepsia 43 Suppl 2: 8–13.
Trimble, M. (1978). “Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review.” Epilepsia 19(3): 241–250.
Trimble, M. R. (2002). “On the use of tranquillisers in epilepsy.” Epilepsia 43 Suppl 2: 25–27.
Trimble, M. R. and A. Hensiek (2002). “On the use of psychotropic drugs in patients with seizure disorder.” In TrimbleM. R. and B. Schmitz (eds) The Neuropsychiatry of Epilepsy. Cambridge, England, Cambridge University Press: 299–312.
Trimble, M. R., N. Rusch, et al. (2000). “Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables.” Seizure 9(4): 249–254.
Umbricht, D., G. Degreef, et al. (1995). “Postictal and chronic psychoses in patients with temporal lobe epilepsy.” Am J Psychiatry 152(2): 224–231.
van der Feltz-Cornelis, C. M., A. P. Aldenkamp, et al. (2008). “Psychosis in epilepsy patients and other chronic medically ill patients and the role of cerebral pathology in the onset of psychosis: a clinical epidemiological study.” Seizure 17(5): 446–456.
Vazquez, B. and O. Devinsky (2003). “Epilepsy and anxiety.” Epilepsy Behav 4 Suppl 4: S20–25.
Wada, Y., N. Hirao, et al. (1999). “Pindolol potentiates the effect of fluoxetine on hippocampal seizures in rats.” Neurosci Lett 267(1): 61–64.
Wang, P. W., C. Nowakowska, et al. (2009). “Divalproex extended-release in acute bipolar II depression.” J Affect Disorddoi: 10.1016/j.jad.2009.10.021.
Watson Laboratories Drug Information (2007). On amoxapine, available at: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=5336.
Weigmann, H., S. Gerek, et al. (2001). “Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.” Ther Drug Monit 23(4): 410–413.
Weilburg, J. B., D. M. Bear, et al. (1987). “Three patients with concomitant panic attacks and seizure disorder: possible clues to the neurology of anxiety.” Am J Psychiatry 144(8): 1053–1056.
Weintraub, D., R. Buchsbaum, et al. (2007). “Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy.” Epilepsy Behav 10(1): 105–110.
Weisler, R. H., J. R. Calabrese, et al. (2008). “Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence.” J Affect Disord 108(1–2): 1–9.
Wender, P. H., F. W. Reimherr, et al. (2010). “A one year trial of methylphenidate in the treatment of ADHD.” J Atten Disorddoi: 10.1177/1087054709356188.
Wernicke, J. F., K. C. Holdridge, et al. (2007). “Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.” Dev Med Child Neurol 49(7): 498–502.
Wilson, K. and P. Mottram (2004). “A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis.” Int J Geriatr Psychiatry 19(8): 754–762.
Wolf, P. and M. R. Trimble (1985). “Biological antagonism and epileptic psychosis.” Br J Psychiatry 146: 272–276.
Wong, Y. W., C. Yeh, et al. (2001). “The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine.” J Clin Psychopharmacol 21(1): 89–93.
Yan, Q. S., J. W. Dailey, et al. (1998). “Anticonvulsant effect of enhancement of noradrenergic transmission in the superior colliculus in genetically epilepsy-prone rats (GEPRs): a microinjection study.” Brain Res 780(2): 199–209.
Yan, Q. S., P. C. Jobe, et al. (1994). “Evidence that a serotonergic mechanism is involved in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats.” Eur J Pharmacol 252(1): 105–112.
Yerevanian, B. I., R. J. Koek, et al. (2007). “Bipolar pharmacotherapy and suicidal behavior. Part I: Lithium, divalproex and carbamazepine.” J Affect Disord 103(1–3): 5–11.
Yilmaz, I., Z. Sezer, et al. (2007). “Mirtazapine does not affect pentylenetetrazole- and maximal electroconvulsive shock-induced seizures in mice.” Epilepsy Behav 11(1): 1–5.
Zaccara, G. and C. M. Cornaggia (2002). “The use of antidepressant and antipsychotic drugs in elderly epilepsy patients.” Epilepsia 43 Suppl 2: 32–36.
Zhang, Z., G. Lu, et al. (2009). “Impaired attention network in temporal lobe epilepsy: a resting FMRI study.” Neurosci Lett 458(3): 97–101.
Zienowicz, M., A. Wislowska, et al. (2005). “The effect of fluoxetine in a model of chemically induced seizures: behavioral and immunocytochemical study.” Neurosci Lett 373(3): 226–231.